Theriva Reports Q3 2026 Results, VIRAGE2 Enrollment Expected to Complete in Q4

Theriva Biologics reported cash of $8.5 million and completed the sale of the SYN-004 portfolio for up to $91 million; the company also noted progress in the VCN-01 metastatic pancreatic cancer trial and ongoing access to capital.